Gastric dumping syndrome is a postoperative complication that frequently occurs after esophageal, gastric, or bariatric surgery and negatively affects the individual's quality of life. Protheragen offers a complete service for the development of preclinical medications for dumping syndrome while also ensuring high-quality and effective support for researchers and scientists in this field.

Overview of Dumping Syndrome

Dumping syndrome is a common postoperative complication. It can be divided into two subtypes based on the timing of the symptoms and the underlying physiopathological mechanisms: early and late dumping. Symptoms from dumping syndrome can pose substantial emotional and social distress. Manifestations include debilitating and severe anxiety, which diminishes their quality of life and may result in severe weight loss if the individual avoids food intake.

Pathogenesis of Dumping Syndrome

The process of early dumping syndrome may be ascribed to the accelerated movement of nutrients to the small intestine, which sets off a series of physiological processes. Early dumping occurs during the hour following a meal when there is a release of gastrointestinal hormones during the rapid expulsion of food into the small intestine leading to a quick shift of fluid into the intestinal lumen. This rapid release of the hormone leads to a spectrum of symptoms termed gastrointestinal vasomotor. Late dumping begins 1-3 hours after eating carbohydrates when hypoglycemia sets in due to the excessive insulin release induced by incretin mechanisms.

Fig.1 Pathophysiology and potential therapeutic objectives in dumping syndrome. (Scarpellini, E., et al., 2020)

Therapeutics Development for Dumping Syndrome

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

At Protheragen, we always emphasize the specific demands of each client and provide solutions based on common research aims and objectives. We understand the importance of providing comprehensive services and offer support at every stage such as diagnostic, therapeutic, and development of disease models which ensures that we assist in the research progress of dumping syndrome seamlessly.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

These animal models are extremely valuable for understanding diseases and evaluating novel therapies. Our company specializes in creating preclinical animal models that closely mimic the pathophysiology of dumping syndrome.

• Surgery Model
  Involve surgical procedures to induce rapid gastric emptying or alter the anatomy of the gastrointestinal tract to replicate dumping syndrome symptoms.
• Chemical-induced Model
  Using substances like hormones induces symptoms resembling dumping syndrome in animals.

Emphasizing Protheragen's capacity to deliver comprehensive preclinical investigations alongside pharmacokinetic analyses and biosafety evaluations. Our streamlined procedures and effective workflows facilitate prompt and economical drug development solutions. Should you have an interest in our services, please do not hesitate to reach out to us for further details.

Reference

• Scarpellini, Emidio et al. "International consensus on the diagnosis and management of dumping syndrome." Nature reviews. Endocrinology 16.8 (2020): 448-466.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.